浙江佐力药业股份有限公司 未来三年（2025-2027年）股东回报规划 为完善和健全浙江佐力药业股份有限公司（以下简称"公司"）的利润分配政 策，增强利润分配的透明度，保证投资者分享公司的发展成果，引导投资者形成 稳定的回报预期，根据中国证监会《上市公司监管指引第 3 号——上市公司现金 分红》等相关文件要求以及《公司章程》的规定，结合公司实际情况，制定了《未 来三年（2025-2027 年）股东回报规划》（以下简称"《股东回报规划》"），具体 内容如下： 一、公司制定《股东回报规划》考虑的因素 公司着眼于长远和可持续发展，在综合考虑公司发展战略规划、公司实际情 况和发展目标、股东要求和意愿、社会资金成本以及外部融资环境等因素的基础 上，结合公司当前及未来盈利规模、现金流量状况、发展所处阶段、项目投资资 金需求、外部融资环境等情况，建立对投资者持续、稳定、科学的回报规划与机 制，从而对利润分配做出制度性安排，以保证利润分配政策的连续性和稳定性。 二、公司制定《股东回报规划》的制定原则 在符合国家相关法律、法规及《公司章程》的前提下，公司将充分重视对投 资者的合理投资回报并兼顾公司的可持续发展，在充分考虑股东利 ...

证券代码：300181 证券简称：佐力药业 公告编号：2025-065 浙江佐力药业股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板 上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 19 日 14:00 6、会议的股权登记日：2025 年 12 月 12 日 7、出席对象： （1）截至 2025 年 12 月 12 日（星期五）下午收市时在中国证券登记结算有 限责任公司深圳分公司登记在册的公司全体股东。上述公司全体股东均有权出席 本次股东会，并可以以书面形式委托代理人出席会议和参加表决，该股东代理人 可以不必是公司股东； （2）公司董事和高级管理人员； （2）网络投票 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江佐力药业股份有限公司（以下简称"公司"）第八届董事会第十次（临时） 会议于 2025 年 12 月 2 日在公司会议室以现场结合通讯方式召开。会议通知于 2025 年 11 月 26 日以专人送达、电话、传真及电子邮件等相结合方式送达各董 事。会议应出席董事 9 人，实际出席董事 9 人。会议由公司董事长俞有强先生主 持，公司高管列席会议。会议的召开符合《中华人民共和国公司法》《公司章程》 的规定。 二、董事会会议审议情况 1、审议通过《关于公司符合向不特定对象发行可转换公司债券条件的议案》 根据《公司法》《证券法》以及《上市公司证券发行注册管理办法》等法律 法规及规范性文件的规定，公司董事会经过对公司实际情况进行认真分析、逐项 自查，认为公司各项条件满足现行法律、法规和规范性文件中关于创业板上市公 司向不特定对象发行可转换公司债券的有关规定，具备向不特定对象发行可转换 公司债券的资格和条件。 证券代码：300181 证券简称：佐力药业 公告编号：2025-060 浙江佐力药业股份有限 ...

人民财讯12月2日电，佐力药业（300181）12月2日公告，公司拟向不特定对象发行可转换公司债券募集 资金不超过15.56亿元，用于智能化中药大健康工厂(一期)、"乌灵+X"产品研发项目及补充流动资金。 ...

格隆汇12月2日｜佐力药业(300181.SZ)公告称，公司计划向不特定对象发行可转换公司债券募集资金总 额不超过15.56亿元，扣除发行费用后的募集资金净额拟用于智能化中药大健康工厂(一期)、"乌灵 +X"产品研发项目及补充流动资金。 ...

佐力药业公告，公司拟向不特定对象发行可转换公司债券募集资金不超过人民币15.56亿元，扣除发行 费用后的募集资金净额拟用于智能化中药大健康工厂（一期）、"乌灵+X"产品研发项目及补充流动资 金。 ...

Macro Strategy - In October, industrial enterprise profits showed a significant decline, with a year-on-year drop from 21.60% in September to -5.5% in October, leading to a cumulative year-on-year growth rate decrease from 3.20% to 1.90% [2] - The A-share market experienced a rebound from November 24 to November 28, with major indices such as the Shanghai Composite Index rising by 1.40% and the ChiNext Index increasing by 4.54% [3][4] - The rebound in A-shares was attributed to a reversal in the market's previous downward momentum, driven by a shift in expectations regarding the Federal Reserve's interest rate decisions and a recovery in the technology sector [3][4] Industry and Company Analysis Traditional Chinese Medicine Industry - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 1.29% last week, the smallest among secondary sub-sectors in the pharmaceutical industry [9] - The price index for TCM materials showed a slight increase of 0.4%, indicating a recovery in market conditions and improved investor sentiment [12] - Multiple regions have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive market structure [13] Investment Recommendations - The report maintains an "overweight" rating for the TCM industry, suggesting three main investment themes: 1. Price governance, focusing on companies with strong R&D capabilities and unique products that can benefit from price reductions [15] 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population, favoring leading TCM brands [16] 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [16] - Recommended stocks include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on companies with strong R&D capabilities and unique products [16]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

Macro Strategy - Recent international gold prices are fluctuating at high levels, with domestic jewelry gold prices also remaining elevated. There is a new trend in gold consumption favoring lighter products like gold bars. Short-term gold prices are expected to maintain high volatility. Consumers should pay attention to international gold price fluctuations if investing, and choose purchasing timing based on their budget for wearing needs [2][3] - From January to October, the national general public budget revenue reached 18.649 trillion yuan, a year-on-year increase of 0.8%. The national general public budget expenditure was 22.5825 trillion yuan, a year-on-year increase of 2%. Securities transaction stamp duty revenue was 162.9 billion yuan, a year-on-year increase of 88.1% [2] - By the end of 2024, the total asset scale of urban commercial banks in China is projected to be 60.15 trillion yuan, a 134-fold increase since 1995, accounting for 13.53% of the banking financial institutions, with a market share increase of 8.24 percentage points. The non-performing loan ratio is 1.76%, and the provision coverage ratio is 188.08% [2] Industry and Company Medical Services Industry - The medical and biological sector rose by 3.29%, ranking fifth among the 31 first-level industries. The Shanghai and Shenzhen 300 Index fell by 1.08%, indicating that the medical sector outperformed the index by 4.37 percentage points [6] - The PE (ttm) of the medical services sector is 33.47X, with a PB (lf) of 3.37X. The PE increased by 0.51X and the PB increased by 0.05X compared to the previous week [7][8] - The TIDES CRDMO market is expected to grow significantly, with the global market projected to increase from 2.1 billion USD in 2018 to 5.5 billion USD in 2023, with a CAGR of 20.9%, and further to 37.3 billion USD by 2032, with a CAGR of 23.8%. The Chinese market is expected to grow from 200 million USD in 2018 to 800 million USD in 2023, with a CAGR of 37.1%, and to 6.2 billion USD by 2032, with a CAGR of 25.5% [9] - Investment recommendations for the medical services sector include focusing on high-growth companies in the ADC CDMO and TIDES CDMO areas, as well as companies in the third-party testing laboratories and consumer medical sectors [10] Traditional Chinese Medicine Industry - The traditional Chinese medicine sector rose by 4.08%, ranking third among secondary sub-sectors. Companies such as Te Yi Pharmaceutical and Zhongsheng Pharmaceutical performed well, while others like *ST Changyao and ST Huluwa performed poorly [12] - The PE (ttm) for the traditional Chinese medicine sector is 29.25X, with a PB (lf) of 2.47X, indicating a slight increase from the previous week [13][14] - The market for traditional Chinese medicinal materials is experiencing volatility, with an overall supply surplus due to increased arrivals from new harvests. Recent weather conditions have also impacted harvesting [15] - The steady advancement of centralized procurement in the traditional Chinese medicine industry aims to reduce patient medication costs and shift competition towards cost control and quality standards [16][17] - Investment recommendations for the traditional Chinese medicine sector include focusing on companies with competitive advantages in product quality and cost, as well as those benefiting from national reforms and centralized procurement policies [18][19]